Know Cancer

forgot password

The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

Phase 3
18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

Inclusion Criteria:

- Signed informed consent

- Age > 18 years

- Histologically confirmed diagnosis of carcinoma of the prostate

- Stage M0: Patients just starting ADT must be stage M0 [PSA <10 (then bone scan not
needed) or negative bone scan (regardless of PSA)]. Patients already on ADT must
have been M0 at the initiation of ADT and have maintained a stable, low PSA (< 2.0)
on continuous ADT since that time.

- Patients initiating or receiving ADT with a LHRH agonist (with or without an
antiandrogen) and with the intended duration of ADT of at least 12 months from the
time of randomization. Patients undergoing bilateral orchiectomy or with history of
this procedure are also eligible. For patients already on ADT, the therapy must be
continuous, and if there is more than one missed or delayed dose (> 1 mo delay) in
any one year period, the patient is not eligible.

- Patient with a baseline BMD T-score <-2.0 in the lumbar spine (L2-L4) and/or the
total hip are eligible

- Life expectancy of at least 12 months

- Zubrod performance status of 0, 1, or 2

Exclusion Criteria

- Patients who received any bisphosphonate therapy in the past 6 months

- Metabolic bone disease including Paget's disease or hyperparathyroidism or vitamin D
deficiency. Patients with vitamin D deficiency or secondary hyperparathyroidism due
to vitamin D deficiency may be treated and reassessed for consideration for the
trial, as detailed in Appendix 9.

- Radiographic evidence of bone metastases

- Patients who have received treatment with systemic corticosteroids within the past 12
months (short term corticosteroid therapy for up to one month duration, e.g. for
acute illness like asthma exacerbation, is acceptable)

- Patients with prior exposure to anabolic steroids or growth hormone within the past 6

- Current treatment with estrogen or complementary medicines known to contain estrogens

- Patients with previous or concomitant malignancy within the past 5 years except
adequately treated basal or squamous cell carcinoma of the skin, and colonic polyps
with non-invasive malignancy which have been removed

- Patients with nonmalignant conditions which would confound the evaluation of the
primary endpoint, impair tolerance of therapy, or prevent compliance to the protocol,

- uncontrolled infections

- uncontrolled type 2 diabetes mellitus

- diseases with influence on bone metabolism, such as Paget's disease or
uncontrolled thyroid or parathyroid dysfunction

- cardiovascular, renal, hepatic, pulmonary and neurologic/psychiatric diseases
which would prevent prolonged follow-up

- Patients with clinical or radiological evidence of existing fracture in the lumbar
spine or either hip

- Patients with history of lumbar spine surgery that directly involved the bone or
resulted in implanted hardware; or rendered the lumbar spine not evaluable (Some
patients with a history of laminectomy alone may qualify).

- Patients with history of unilateral fracture of hip due to trauma or unilateral hip
surgery and the other hip and lumbar spine are not evaluable.

- Patients for whom the lumbar spine and at least one hip are not evaluable for any

- Patients treated with systemic investigational drugs(s) and /or device(s) within the
past 30 days

- Patients with any prior treatment for osteoporosis except for calcium and vitamin D

- Patients with abnormal renal function as evidenced by either a serum creatinine
greater than 3 mg/dL or by a calculated creatinine clearance of 40 ml/minute or less
(Use Cockcroft-Gault equation. See Appendix 5).

- Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00

Other protocol-defined exclusion criteria may apply.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Percent change in bone mineral density of the lumbar spine (L2-L4) at 6 and 12 months.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Nirmala Bhoopalam, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hines VA Medical Center


United States: Food and Drug Administration

Study ID:




Start Date:

June 2004

Completion Date:

March 2007

Related Keywords:

  • Prostate Cancer
  • Osteoporosis
  • Prostatic Neoplasms



Washington VA Medical Center Washington, District of Columbia  20422
Hines VA Medical Center Hines, Illinois  60141
Southern AZ VA Health Care System Tucson, Arizona  85723
VA Medical Center-Long Beach Long Beach, California  90822
West Side VMAC Chicago, Illinois  60612
Kansas City VMAC Kansas City, Missouri  64128
VAWNY Buffalo Buffalo, New York  14215